Anticytotoxin effects of amentoflavone to pneumolysin

Biological and Pharmaceutical Bulletin

Volumn 40, Issue 1, 2017, Pages 61-67

  Zhao, Xiaoran ^a   Liu, Bowen ^a   Liu, Shui ^a   Wang, Lin ^a   Wang, Jianfeng ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Amentoflavone; Oligomerization; Pneumolysin; Streptococcus pneumoniae

Indexed keywords

AMENTOFLAVONE; ARGININE; ARGININE 359; BACTERIAL PROTEIN; CHEMICAL COMPOUND; GLUTAMINE; GLUTAMINE 277; PNEUMOLYSIN; SERINE; SERINE 254; UNCLASSIFIED DRUG; BIFLAVONOID; LACTATE DEHYDROGENASE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN;

BACTERIAL INFECTION; CELL CULTURE; CHINESE HERB; CHINESE MEDICINE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; OLIGOMERIZATION; REVIEW; SELAGINELLA TAMARISCINA; SITE DIRECTED MUTAGENESIS; STREPTOCOCCUS PNEUMONIAE; WILD TYPE; ACUTE LUNG INJURY; ANIMAL; C57BL MOUSE; CELL PROTECTION; DRUG EFFECTS; GENETICS; HEMOLYSIS; HUMAN; LUNG; MALE; METABOLISM; PATHOLOGY; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; TUMOR CELL LINE;

ACUTE LUNG INJURY; ANIMALS; BACTERIAL PROTEINS; BIFLAVONOIDS; CELL LINE, TUMOR; CYTOPROTECTION; HEMOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; LUNG; MALE; MICE, INBRED C57BL; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 85008178952     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b16-00598     Document Type: Review

References (23)

1. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteriamediated disease. Nat. Rev. Drug Discov., 9, 117-128 (2010).
2. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol. Mol. Biol. Rev., 65, 187-207 (2001).
3. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin. Infect. Dis., 26, 1188-1195 (1998).
4. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature, 399, 590-593 (1999).
5. Alouf JE. Cholesterol-binding cytolytic protein toxins. Int. J. Med. Microbiol., 290, 351-356 (2000).
6. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon: Official Journal of the International Society on Toxinology, 39, 1681-1689 (2001).
7. Gilbert RJ, Jimenez JL, Chen S, Tickle IJ, Rossjohn J, Parker M, Andrew PW, Saibil HR. Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell, 97, 647-655 (1999).
8. Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J. Nat. Prod., 60, 884-888 (1997).
9. Zhang Z, Sun T, Niu JG, He ZQ, Liu Y, Wang F. Amentoflavone protects hippocampal neurons: anti-inflammatory, antioxidative, and antiapoptotic effects. Neural Regeneration Research, 10, 1125-1133 (2015).
10. Zha X, Xu Z, Liu Y, Xu L, Huang H, Zhang J, Cui L, Zhou C, Xu D. Amentoflavone enhances osteogenesis of human mesenchymal stem cells through JNK and p38 MAPK pathways. J. Nat. Med., 70, 634-644 (2016).
11. Xu P, Jiang EJ, Wen SY, Lu DD. Amentoflavone acts as a radioprotector for irradiated v79 cells by regulating reactive oxygen species (ROS), cell cycle and mitochondrial mass. Asian Pac. J. Cancer Prev., 15, 7521-7526 (2014).
12. Zhao X, Li H, Wang J, Guo Y, Liu B, Deng X, Niu X. Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomers. Mol. Pharmacol., 89, 376-387 (2016).
13. Ragle BE, Karginov VA, Bubeck Wardenburg J. Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative. Antimicrob. Agents Chemother., 54, 298-304 (2010).
14. Laskowski RA, Moss DS, Thornton JM. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol., 231, 1049-1067 (1993).
15. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput., 4, 435-447 (2008).
16. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des., 10, 293-304 (1996).
17. Hu R, Barbault F, Delamar M, Zhang R. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 17, 2400-2409 (2009).
18. Dong J, Qiu J, Zhang Y, Lu C, Dai X, Wang J, Li H, Wang X, Tan W, Luo M, Niu X, Deng X. Oroxylin A inhibits hemolysis via hindering the self-assembly of alpha-hemolysin heptameric transmembrane pore. PLOS Comput. Biol., 9, e1002869 (2013).
19. Gilbert RJ, Rossjohn J, Parker MW, Tweten RK, Morgan PJ, Mitchell TJ, Errington N, Rowe AJ, Andrew PW, Byron O. Self-interaction of pneumolysin, the pore-forming protein toxin of Streptococcus pneumoniae. J. Mol. Biol., 284, 1223-1237 (1998).
20. Schmeck B, Gross R, N'Guessan PD, Hocke AC, Hammerschmidt S, Mitchell TJ, Rosseau S, Suttorp N, Hippenstiel S. Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium. Infect. Immun., 72, 4940-4947 (2004).
21. Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, Xu H, Andalibi A, Feng XH, Zhu H, Huang Y, Zhang W, Weng X, Yan C, Yin Z, Briles DE, Davis RJ, Flavell RA, Li JD. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity, 27, 349-360 (2007).
22. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J. Infect. Dis., 190, 1661-1669 (2004).
23. Cardinali A, Pati S, Minervini F, D'Antuono I, Linsalata V, Lattanzio V. Verbascoside, isoverbascoside, and their derivatives recovered from olive mill wastewater as possible food antioxidants. J. Agric. Food Chem., 60, 1822-1829 (2012).